千金药业：公司定于2026年1月12日在公司会议室召开2026年第一次临时股东会

Group 1 - The company, Qianjin Pharmaceutical, announced that it will hold its first extraordinary general meeting of shareholders for 2026 on January 12, 2026, to review proposals submitted by the 15th meeting of the 11th Board of Directors [1] - For the first half of 2025, the revenue composition of Qianjin Pharmaceutical was as follows: 55.83% from drug manufacturing, 41.72% from drug wholesale and retail, 6.91% from other industries, 1.64% from the production of traditional Chinese medicine materials and decoction pieces, and -6.1% from internal offsets [1] - As of the report date, Qianjin Pharmaceutical has a market capitalization of 5.1 billion yuan [1]